You Position: Home > Paper
A randomized controlled clinical trial on the treatment of entecavir versus lamivudine in patients with chronic hepatitis B
( views:194, downloads:24 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1674-2397.2009.06.013
- Key Word:
- 肝炎病毒;乙型;肝炎;乙型;慢性;恩替卡韦;拉米夫定;Hepatitis B virus;Chronic hepatitis B;Entecavir;Lamivudine
Abstract： @@ 慢性乙型肝炎(CHB)的抗病毒治疗可抑制HBV复制,阻止或延缓肝脏疾病的进展,从而改善疾病预后,提高患者的生活质量.恩替卡韦(ETV)是新一代抗HBV核苷类似物,在体外实验、动物模型和人体临床试验中均显示出强大的抑制HBV复制作用,疗效优于拉米夫定(LAM)和阿德福韦酯(ADV)[2].为进一步确定ETV的疗效及安全性,笔者对150例核苷(酸)类似物初治的CHB患者分别给予ETV和LAM治疗,进行随机对照临床研究.
- [1]刘林华,陈新月.抗乙型肝炎病毒新药--恩替卡韦[J].2006,(1).
- [2]中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南[J].2005,(12).
- [3]P, Honkoop,R A, De Man.Entecavir: a potent new antiviral drug for hepatitis B.[J].2003,12(4).
- [4]Tim, Shaw,Stephen, Locarnini.Entecavir for the treatment of chronic hepatitis B.[J].2004,2(6).